Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CO-1.01 vs gemcitabine in first-line metastatic pancreatic adenocarcinoma (phase II)
2009-018240-23Phase 2Completed
- Sponsor
- Clovis Oncology
- Start
- Feb 2010
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of gemcitabine elaidate in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Clovis Oncology. Primary endpoint: Overall survival in low hENT1 expression patients. Started Feb 2010; status: completed.
02
Drugs
gemcitabine elaidate
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2009-018240-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-018240-23.